BV-173 Cells
USD$395.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The BV-173 cell line originates from the peripheral blood of a patient diagnosed with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML), established in 1980. This cell line is particularly noted for its Ph+ status, which is indicative of a specific chromosomal abnormality involving the translocation between chromosome 9 and chromosome 22. This translocation, often referred to as the Philadelphia chromosome, results in the BCR-ABL fusion gene, a critical molecular hallmark that drives the pathogenesis of CML by promoting leukemic cell proliferation and survival. BV-173 cells are used extensively in hematological research as a model to study the cellular and molecular mechanisms of CML, especially in the context of drug resistance and the cellular response to tyrosine kinase inhibitors (TKIs), which target the BCR-ABL fusion protein. The cell line has been instrumental in preclinical studies for evaluating new therapeutic strategies and understanding the biology of CML. BV-173 exhibits characteristics typical of myeloid lineage cells and is often used to study signal transduction pathways that are deregulated in CML due to the BCR-ABL oncogene. |
|---|---|
| Organism | Human |
| Tissue | Blood |
| Disease | Chronic myeloid leukemia |
Characteristics
| Age | 45 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Cell type | Undifferentiated blast cells |
| Growth properties | Suspension |
Regulatory Data
| Citation | BV-173 (Cytion catalog number 300133) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_0181 |
Biomolecular Data
| Reverse transcriptase | Negative (ELISA) |
|---|---|
| Ploidy status | T(9, 22) Modal Number: 2n=46 |
| Mutational profile | B2a2 BCR-ABL |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% heat-inactivated FBS |
| Doubling time | 35 hours |
| Subculturing | Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth. |
| Seeding density | 1 x 105 cells/ml |
| Fluid renewal | 2 to 3 times per week |
| Post-Thaw Recovery | Allow the cells to recover from the freezing process for at least 48 hours. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300133-280623 | Certificate of Analysis | 23. May. 2025 | 300133 |
| 300133-070525 | Certificate of Analysis | 21. Jul. 2025 | 300133 |